Ruxolitinib
JAK kinase inhibitor
Product Specifications
Background
Ruxolitinib is a Janus-associated kinases (JAK) inhibitor, which specifically inhibits JAK1 and JAK3. JAKs are known to active the signaling of certain growth factor receptors and cytokines.
CAS Number
941678-49-5
Product Name Alternative
(3R) -3- (4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cell Signaling | Cancer | Apoptosis | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors
Purity
>98%
Weight
0.025
Format
Off-white solid
Solubility
Soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml)
Molecular Formula
C17H18N6
Molecular Weight
306.4
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Aittomäki S., & Pesu M. (2014) Basic & Clin. Pharm.Toxic. 114(1): 18–23.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E-CL-H1304-01 24 Tests
Human PAF (Platelet Activating Factor) CLIA Kit
Sign In for Pricing
View Details E-CL-H1304-02 48 Tests
Human PAF (Platelet Activating Factor) CLIA Kit
Sign In for Pricing
View Details E-CL-H1304-03 96 Tests
Human PAF (Platelet Activating Factor) CLIA Kit
Sign In for Pricing
View Details 
